Eurus Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$5.6M
- Investors
-
9
Eurus Therapeutics General Information
Description
Developer of a novel genome editing technology designed to offer advancements in the medical industry. The company develops a new gene therapy with therapeutic strategies that can induce simple and precise genome editing without the use of exogenous proteins such as Cas, enabling the healthcare sector to solve the problems faced by the CRISPR/Cas system.
Contact Information
Website
eurus-tx.comCorporate Office
- 2-26-1 Muraokahigashi
- Fujisawa, Kanagawa
- Japan
Corporate Office
- 2-26-1 Muraokahigashi
- Fujisawa, Kanagawa
- Japan
Eurus Therapeutics Timeline
Eurus Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC | 27-Jun-2025 | $5.6M | Completed | Startup | ||
| 1. Seed Round | 29-Sep-2023 | Completed | Startup |
Eurus Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Class A-2 Preferred Shares | ||||||||
| A Preferred |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Eurus Therapeutics Patents
Eurus Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026094932-A1 | Double-stranded nucleotide complex for modification of target nucleotide sequence | Pending | 29-Oct-2024 | ||
| JP-2026078993-A | Double-stranded nucleotide complexes for alteration of target nucleotide sequences | Pending | 29-Oct-2024 | ||
| AU-2024260090-A1 | Non-natural polynucleotides for modification of target nucleotide sequence | Pending | 26-Apr-2023 | ||
| EP-4703472-A1 | Non-natural polynucleotides for modification of target nucleotide sequence | Pending | 26-Apr-2023 | ||
| JP-2025092562-A | Non-natural polynucleotides for modification of target nucleotide sequence | Pending | 26-Apr-2023 | C12N15/102 |
Eurus Therapeutics Signals
Eurus Therapeutics Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Kyoto Capital Partners (Japan) | Venture Capital | Minority | ||
| RDiscovery Corporation | Corporation | Minority | ||
| Remiges Ventures | Venture Capital | Minority | ||
| SMBC Venture Capital | Corporate Venture Capital | Minority | ||
| Summit Pharmaceuticals International | Corporation | Minority |
Eurus Therapeutics FAQs
-
When was Eurus Therapeutics founded?
Eurus Therapeutics was founded in 2021.
-
Where is Eurus Therapeutics headquartered?
Eurus Therapeutics is headquartered in Fujisawa, Japan.
-
What is the size of Eurus Therapeutics?
Eurus Therapeutics has 10 total employees.
-
What industry is Eurus Therapeutics in?
Eurus Therapeutics’s primary industry is Drug Discovery.
-
Is Eurus Therapeutics a private or public company?
Eurus Therapeutics is a Private company.
-
What is the current valuation of Eurus Therapeutics?
The current valuation of Eurus Therapeutics is .
-
What is Eurus Therapeutics’s current revenue?
The current revenue for Eurus Therapeutics is .
-
How much funding has Eurus Therapeutics raised over time?
Eurus Therapeutics has raised $7.23M.
-
Who are Eurus Therapeutics’s investors?
Kyoto Capital Partners (Japan), RDiscovery Corporation, Remiges Ventures, SMBC Venture Capital, and Summit Pharmaceuticals International are 5 of 9 investors who have invested in Eurus Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process